The briefing
A roundup from IDWeek 2026 highlights oral olorofim matching AmBisome in invasive aspergillosis and aztreonam–avibactam retaining activity as MBL-producing CRE rise. It also reports pritelivir reducing hospitalizations in refractory HSV and zelicapavir shortening RSV symptoms in high-risk adults.
Original headline
ID Week Highlights Part 1